SEO URLwww.firestrike.ai/deals/bluejay-therapeutics-mirum-acquisition-2026-6
acquisitionAnnounced · Jan 26, 2026biotechnologySource · CredibleArticle · Factual
Mirum acquires Bluejay Therapeutics
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
Deal value
$620M
Target
Bluejay Therapeutics
Acquirer
Mirum
Full Acquisition
Status
Pending
Mirum agreed to acquire Bluejay Therapeutics. Reported deal value: $620M. Status: Pending. Sector: biotechnology. Target headquarters context: United States.
This page summarizes publicly available information about the transaction as of 2026-01-26. Figures and status may change as filings and press coverage update.
Mirum Pharmaceuticals , Inc. , a leading rare disease company, today announced the successful completion of its acquisition of Bluejay Therapeutics , a privately held biotechnology company focused on viral and liver disease s
Deal timeline
Announced
Jan 26, 2026 · businesswire.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in biotechnology with a reported deal value of $620M. Figures and status may change as sources update.
Sources: businesswire.com · Primary article · FireStrike proprietary index